Hepatocytes and Chondrocytes from Adherent Placental StemCells; And CD34+ ,CD45- Placental Stem Cell-Enriched Cell Populations
First Claim
Patent Images
1. A method of producing a hepatocyte, comprising contacting a CD10+, CD34−
- , CD105+ and CD200+ placental stem cell with sodium butyrate under conditions and for a time sufficient for said stem cell to exhibit a characteristic of a hepatocyte.
3 Assignments
0 Petitions
Accused Products
Abstract
Provided herein are methods and compositions for the production of hepatocytes from placenta stem cells. Further provided herein is the use of such hepatocytes in the treatment of, and intervention in, for example, trauma, inflammation, and degenerative disorders of the liver. Also provided herein are compositions and methods relating to combinations of nanofibrous scaffolds and adherent placental stem cells and methods of using the same in cartilage repair. Finally, provided herein are compositions and methods relating to nonadherent, CD34+CD45− stem cells from placenta.
202 Citations
37 Claims
-
1. A method of producing a hepatocyte, comprising contacting a CD10+, CD34−
- , CD105+ and CD200+ placental stem cell with sodium butyrate under conditions and for a time sufficient for said stem cell to exhibit a characteristic of a hepatocyte.
- View Dependent Claims (2, 3, 4, 5, 6)
-
7. A mouse comprising human placental stem cell-derived hepatocytes or hepatogenic cells, wherein said mouse is produced by a method comprising the steps of:
-
a. irradiating said mouse with gamma radiation sufficient to kill substantially all of the endogenous bone marrow cells; b. administering to said mouse sufficient bone marrow or bone marrow-derived cells from a NOD/SCID mouse to reconstitute the hematopoietic system of the mouse; and c. transplanting to said mouse a plurality of hepatocytes or hepatogenic cells, wherein said hepatocytes or hepatogenic cells are differentiated from a plurality of CD10+, CD34−
, CD105+, CD200+ placental stem cells. - View Dependent Claims (8, 9, 10, 11, 36)
-
- 12. A method of identifying an antiviral agent, comprising contacting the mouse of claim 12 with a compound of interest, wherein serum from said mouse has detectable levels of virus, and wherein said compound is an antiviral agent if said contacting results in a detectable reduction in the amount of said virus in serum from said mouse, compared to serum from said mouse not contacted with the compound of interest.
-
18. A composition comprising a plurality of cells encapsulated in alginate, wherein said cells are differentiated from placental stem cells, and wherein said cells express at least one marker of a hepatocyte not expressed by, or expressed to a detectably different degree than, an adherent placental stem cell that is CD10+, CD34−
- , CD105+ and CD200+.
- View Dependent Claims (19, 20, 21)
-
22. A composition comprising isolated adherent CD10+, CD34−
- , CD105+, CD200+ placental stem cells and an electrospun nanofibrous scaffold.
- View Dependent Claims (23, 24, 25, 28, 29)
-
26. A method of making a composition comprising contacting adherent CD10+, CD34−
- , CD105+, CD200+ placental stem cells with an electrospun nanofibrous scaffold, wherein said nanofibrous scaffold is made by electrospinning PLLA or PLGA at about 20 kV at about 30 cm needle to collector distance and about 0.05 mL/min. to about 0.1 mL/min flow rate, wherein said PLLA or PLGA are in solution at about 10% w/w to about 20% w/w.
-
27. An isolated cell population enriched for CD34+, CD45−
- placental stem cells.
- View Dependent Claims (30, 31, 32, 33, 34, 35)
-
37. A method of producing a CD34+, CD45−
- placental stem cell population, comprising selecting CD34+ cells from a population of placental cells to form a population of CD34+ placental cells, and removing from said population of CD34+ placental cells CD45+ cells, wherein a CD34+, CD45−
placental stem cell population is produced.
- placental stem cell population, comprising selecting CD34+ cells from a population of placental cells to form a population of CD34+ placental cells, and removing from said population of CD34+ placental cells CD45+ cells, wherein a CD34+, CD45−
Specification